<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964275</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000639720</org_study_id>
    <secondary_id>HCB-MVTEP</secondary_id>
    <secondary_id>RB 08-062</secondary_id>
    <secondary_id>INCA-RECF0945</secondary_id>
    <secondary_id>EUDRACT-2008-004135-38</secondary_id>
    <nct_id>NCT00964275</nct_id>
  </id_info>
  <brief_title>Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein</brief_title>
  <acronym>MVTEP</acronym>
  <official_title>Study of Positron Emission Tomography With 18-fluorodeoxyglucose in Detecting Cancer in Patients With Idiopathic Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as fludeoxyglucose F 18 positron emission tomography,&#xD;
      may help find and diagnose cancer. It is not yet known whether standard diagnostic procedures&#xD;
      are more effective when given with or without fludeoxyglucose F 18 positron emission&#xD;
      tomography in finding cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying fludeoxyglucose F 18 positron emission&#xD;
      tomography given together with standard diagnostic procedures to see how well it works&#xD;
      compared with standard diagnostic procedures alone in finding cancer in patients with a blood&#xD;
      clot in a vein.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Demonstrate the efficacy, in terms of increased numbers of cancer diagnoses, of PET-CT&#xD;
           with 18-FDG in patients with idiopathic venous thromboembolism.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the risk of cancer detected at 1 year.&#xD;
&#xD;
        -  Assess whether PET allows earlier detection of cancer.&#xD;
&#xD;
        -  Evaluate survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      All patients undergo standard (clinical and biological) diagnostic tests for cancer. Patients&#xD;
      are randomized to 1 of 2 diagnostic arms.&#xD;
&#xD;
        -  Arm I: Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard&#xD;
           methods.&#xD;
&#xD;
        -  Arm II: Patients only undergo standard diagnostic methods. Patients are followed up for&#xD;
           2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cancers diagnosed</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Thromboembolism</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients only undergo standard diagnostic methods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic procedure</intervention_name>
    <description>Standard diagnostic procedures followed</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>PET with flueoxyglucose F 18</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of idiopathic venous thromboembolism (IVTE) meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Newly diagnosed&#xD;
&#xD;
               -  Recurrent disease controlled by anticoagulant therapy&#xD;
&#xD;
          -  No IVTE caused by a reversible major risk factor&#xD;
&#xD;
          -  No IVTE caused by a major constitutional risk factor, including any of the following:&#xD;
&#xD;
               -  Antiphospholipid antibody syndrome&#xD;
&#xD;
               -  Antithrombin deficit&#xD;
&#xD;
               -  Protein C&#xD;
&#xD;
               -  Protein S&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No other known active cancer at the onset of IVTE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Yves Salaun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brest - Hopital De La Cavale Blanche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brest - Hopital De La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>thromboembolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

